Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts

Cancer Research

Volumn 58, Issue 3, 1998, Pages 473-478

  Selig, Ruth A ^a   White, Les ^a   Gramacho, Cilinia ^a   Sterling Levis, Katy ^a   Fraser, Ian W ^b   Naidoo, Daya ^b  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; FERRITIN; HEMOGLOBIN; IRON; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAPERITONEAL DRUG ADMINISTRATION; IRON CHELATION; IRON METABOLISM; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR GROWTH; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; CHILD, PRESCHOOL; DEFEROXAMINE; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; FERRITINS; HEMOGLOBINS; HUMANS; IRON; IRON CHELATING AGENTS; LIVER; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; PYRIDONES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032006798     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Hann, H-W. L., Evans, A. E., Siegel, S. E., Wong, K. V., Sather, H., Dalton, A., Hammond, D., and Seeger, R. C. Prognostic importance of serum ferritin in patients with stages III and IV neuroblastoma: The Children's Cancer Study Group experience. Cancer Res., 45: 2843-2848, 1985.
2. Moroz, C., Giler, S., and Kupfer, B. Lymphocytes bearing surface ferritin in patients with Hodgkin's disease and breast cancer. N. Engl. J. Med., 296: 1172-1173, 1977.
3. Jacobs, A., Jones, B., Ricketts, C., Bulbrook, R. D., and Wang, D. Y. Serum ferritin concentration in early breast cancer. Br. J. Cancer, 34: 286-290, 1976.
4. Hann, H-W. L., Stahlhut, M. W., and Evans, A. E. Basic and acidic isoferritins in the sera of patients with neuroblastoma. Cancer (Phila.), 62: 1179-1182, 1988.
5. Hann, H-W. L., Stahlhut, M. W., and Evans, A. E. Source of increased ferritin in neuroblastoma: studies with concanavalin A-sepharose binding. J. Natl. Cancer Inst., 76: 1031-1033, 1986.
6. Hazard, J. T., and Drysdale, J. W. Ferritinaemia in cancer. Nature (Lond.), 265: 755-756, 1977.
7. Hann, H-W. L., Stahlhut, M. W., and Millman, I. Human ferritins present in the sera of nude mice transplanted with human neuroblastoma or hepatocellular carcinoma. Cancer Res., 44: 3898-3901, 1984.
8. Blatt, J., and Stitely, S. Antineuroblastoma activity of desferoxamine in human cell lines. Cancer Res., 47: 1749-1750, 1987.
9. Weinberg, E. D. Iron withholding: a defence against infection and neoplasia. Physiol. Rev., 64: 65-100, 1984.
10. Selig, R. A., Madafiglio, J., Haber, M., Norris, M. D., White, L., and Stewart, B. W. Ferritin production and desferrioxamine cytotoxicity in human neuroblastoma cell lines. Anticancer Res., 13: 721-726, 1993.
11. Porter, J. B., Morgan, J., Hoyes, K. P., Burke, L. C., Huehns, E. R., and Hider, R. C. Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice. Blood, 76: 2389-2396, 1990.
12. Kontoghiorghes, G. J. Dose response studies using desferrioxamine and orally active chelators in a mouse model. Scand. J. Haematol., 37: 63-70, 1986.
13. Olivieri, N. F., Koren, G., Hermann, C., Bentur, Y., Chung, D., Klein, J., St. Louis, P., Freedman, M. H., McClelland, R. A., and Templeton, D. M. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet, 336: 1275-1279, 1990.
14. Sterling-Levis, K., White, L., Trickett, A. E., Gramacho, C., Pittman, S. M., and Tobias, V. Heterotransplantation of early B-lineage acute lympholastic leukemia using a solubilized attachment matrix (Matrigel). Cancer Res., 53: 1222-1225, 1993.
15. Tomayko, M. M., and Reynolds, C. P. Determination of subcutaneous tumour size in athymic (nude) mice. Cancer Chemother. Pharmacol., 24: 148-154, 1989.
16. Grail, A., Hancock, B. W., and Harrison, P. Serum ferritin in normal individuals and patients with malignant lymphoma and chronic renal failure measurement with seven different commercial immunoassay techniques. J. Clin. Pathol., 35: 1204-1212, 1982.
17. Revenant, M. C., "Sandwich" enzyme immunoassay for serum ferritin with polypylene test tubes as solid-phase. Clin. Chem., 29: 681-683, 1983.
18. Knowles, M., In: E. Rothery (ed.), Analytical Methods for Graphite Tube Atomisers, pp. 46-47. Mulgrave, Victoria, Australia: Varian Australia P/L, 1988.
19. Arosio, P., Adelman, T. G., and Drysdale, J. W. On ferritin heterogeneity: further evidence for heteropolymers. J. Biol. Chem., 253: 4451-4458, 1978.
20. Hann, H-W. L. Inhibitory effects of isoferritins from tumour and non-tumour tissues on E-rosette formation. Lancet. 336: 43, 1984.
21. Crichton, R. R., and Charloteaux-Wauters, M. Iron transport and storage. Eur. J. Biochem., 164: 485-506, 1987.
22. Weinberg, K. Novel uses of deferoxamine. Am. J. Ped. Hematol/Oncol., 12: 9-13, 1990.
23. Hoffbrand, A. V., Ganeshaguru, K., Hooton, J. W. L., and Tattersall, M. H. N. Effect of iron efficiency and desferrioxamine on DNA synthesis in human cells. Br. J. Haematol., 33: 517-526, 1976.
24. Hann, H-W. L., Stahlhut, M. W., Rubin, R., and Maddrey, W. C. Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice Cancer (Phila.), 70: 2051-2056, 1992.
25. Becton, D. L., and Bryles, P. Deferoxamine inhibition of human neuroblastoma viability and proliferation. Cancer Res., 48: 7189-7192, 1988.
26. Iancu, T. C., Shiloh, H., and Kedar, A. Neuroblastomas contain iron-rich ferritin. Cancer (Phila.), 61: 2497-2502, 1988.
27. Faulk, W. P., and Galbraith, M. P. Trophoblast transferrin and transferrin receptors in the host-parasite relationship of human pregnancy. Proc. R. Soc. Lond. Ser. B. Biol. Sci., 204: 83-97, 1979.
28. Blatt, J., Taylor, S. R., and Kontoghiorghes, G. J. Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines. Cancer Res., 49: 2925-2927, 1989.
29. Blatt, J. Deferoxamine in children with recurrent neuroblastoma. Anticancer Res., 14: 2109-2112, 1994.
30. Donfrancesco, A., Deb, G., Dominici, C., Pileggi, D., Castello, M. A., and Helson, L. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res., 50: 4929-4930, 1990.
31. Siimes, M. A., Addiego, J. E., Jr., and Dallman, P. R. Ferritin in serum: diagnosis of iron deficiency and iron overload in infants and children. Blood, 43: 581-590, 1974.
32. Donfrancesco, A., Deb, G., Angioni, A., Maurizio, C., Cozza, R., Jenkner, A., Landolfo, A., Boglino, C., and Helson, L. D-CECaT: a breakthrough for patients with neuroblastoma. Anti-Cancer Drugs, 4: 317-321, 1993.
33. Donfrancesco, A., De Bernardi, B., Carli, M., Mancini, A., Nigro, M., De Sio, L., Casale, F., Bagnulo, S., Helson, L., and Deb, L. (for the Italian Neuroblastoma Cooperative Group). Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: preliminary results. Eur. J. Cancer, 31A: 612-615, 1995.
34. Tumilowitcz, J. J., Nichols, W. W., Cholon, J. J., and Greene, A. E. Definition of a continuous human cell line derived from neuroblastoma. Cancer Res, 30: 2110-2118, 1970.
35. Porter, J. B., Singh, S., Hoyes, K. P., Epemolu, O., Abeysinghe, R. D., and Hider, R. C. Lessons from preclinical and clinical studies with 1,2-diethyl-3-hydroxypyridin-4-one, CP94 and related compounds. In: C. Hershko (ed.), Progress in Iron Research, pp. 361-370. New York: Plenum Publishing Corp., 1994.
36. Nathan, D. G. An orally active iron chelator. N. Engl. J. Med., 14: 953-954, 1995.
37. Kontoghiorghes, G. J., Goddard, J. G., Barlett, A. N., and Sheppard, L. Pharmacokinetic studies in humans with oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin. Pharmacol. Ther., 48: 255-261, 1990.
38. Olivieri, N. F., Brittenham, G. M., Matsui, D., Berkovitch, M., Blendis, L. M., Cameron, R. G., McClelland, R. A., Lui, P. P., Templeton, D. M., and Koren, G. Iron-chelation therapy with oral deferiprone in patients with thalassemia major N. Engl. J. Med., 332: 918-922, 1995.
39. Richardson, D. R., and Ponka, P. The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis. J. Lab. Clin. Med., 124: 660-671, 1994.
40. Bridges, K. R., and Bunn, H. F. In: J. D. Wilson, E. Braunwald, K. J. Isselbacher, R. G. Petersdorf, J. B. Martin, A. S. Fauci, and R. K. Root (eds.), Harrison's Principles of Internal Medicine, Ed. 12, pp. 1519-1575. New York: McGraw Hill, Inc., 1991.
41. Skala, J. P., Rogers, P. C. J., Fryer, C. J. H., and Rodriguez, W. C. Deferoxamine as a purging agent for autologous bone marrow grafts in neuroblastoma. Prog. Clin. Biol. Res., 377: 71-78, 1992.